Kymab has been profiled in Nature Publishing Group's Biopharma Dealmakers.
From the publishers of Nature, BioPharma Dealmakers delivers insights into and profiles from companies showcasing their pipeline products, technologies, therapeutic focus and partnering strategies.
The profile explains how "the Kymab team has the technology, investment and decades of commercial experience in discovery and development to deliver human mAb therapeutics to the clinic."
Read the Dealmakers article "Kymouse: the 100-trillion antibody mouse"
You'll need the free Adobe Reader to view the PDF article.